For research use only. Not for therapeutic Use.
Benufutamab（Cat No.:I042159）is an investigational monoclonal antibody designed to target and inhibit the protein HER3 (human epidermal growth factor receptor 3), which is involved in cancer cell signaling and tumor growth. HER3 plays a key role in the development of various cancers, including breast, lung, and head and neck cancers. By blocking HER3, benufutamab aims to disrupt cancer cell survival and enhance the effectiveness of cancer treatments. It is being studied in clinical trials for its potential to treat HER3-positive cancers, focusing on improving patient outcomes through targeted therapy.
| Catalog Number | I042159 |
| CAS Number | 2109730-69-8 |
| Purity | ≥95% |
